Frontiers in Psychiatry
October 9, 2023
Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, S. Joshi et al.
6 citations
Introduction Subanesthetic ketamine is a rapidly acting antidepressant that has also been found to improve neurocognitive performance in adult patients with treatment resistant depression (TRD). Provisional evidence suggests that ketamine may induce change in hippocampal volume and that larger pre-treatment volumes might be related to positive clinical outcomes. Here, we examine the effects of...
New England Journal of Medicine
October 4, 2023
Andreas Reif, Istvan Bitter, Jozefien Buyze et al.
197 citations
BACKGROUND: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with...
Brain, behavior, and immunity
October 1, 2023
Xinying Zhang, Teng He, Zifeng Wu et al.
CD38 is involved in immune responses, cell proliferation, and has been identified in the brain, where it is implicated in inflammation processes and psychiatric disorders. We hypothesized that dysfunctional CD38 activity in the brain may contribute to the pathogenesis of depression. To investigate the underlying mechanisms, we used a lipopolysaccharide (LPS)-induced depression model and...
Biological Psychiatry Global Open Science
October 1, 2023
Ben Julian A Palanca, Charles R Conway, Thomas Zeffiro et al.
Nitrous oxide holds promise in the treatment of major depressive disorder. Its psychotropic effects and NMDA receptor antagonism have led to comparisons with ketamine. Despite longstanding use, persistent effects of nitrous oxide on the brain have not been characterized. Sixteen healthy volunteers were recruited in a double-blind crossover study. In randomized order, individuals underwent a...
Focus (American Psychiatric Publishing)
October 1, 2023
Farhan Fancy, Nelson B Rodrigues, Joshua D. Di Vincenzo et al.
4 citations
Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. This study was conducted in a community clinic in Mississauga, Ontario (Canadian...
International Journal of Neuropsychopharmacology
September 25, 2023
Szabolcs Koncz, Noémi Papp, Dóra Pothorszki et al.
29 citations
Abstract Background Racemic ketamine consists of two enantiomers, namely (R)-ketamine and (S)-ketamine, with distinguishable pharmacological properties. Both enantiomers have been reported to show rapid antidepressant effects in rodents. Currently, the (S)-enantiomer has been approved for the treatment of major depression, whereas (R)-ketamine failed to show antidepressant effect in recent...
JHLT Open
September 22, 2023
Anna Bovill Shapiro, Mohit Chauhan, Archer Kilbourne Martin et al.
1 citation
A 68-year-old with a history of ischemic cardiomyopathy, chronic kidney disease, hypertension, and anxiety was admitted to the intensive care unit (ICU) in cardiogenic shock. After an intubation and several days in the ICU, he expressed hopelessness with further care and was considering a transition to hospice. The treatment team was concerned that clinical depression was influencing his...
Journal of Affective Disorders
September 20, 2023
Isaure Estrade, Anne-Cécile Petit, Vincent Sylvestre et al.
Background: The efficacy of esketamine in treatment-resistant depression (TRD) has been confirmed. However, its administration is expensive and restrictive, with limited knowledge on how long the treatment should be continued. Predicting the treatment outcome would benefit patients and alleviate the global treatment cost. We aimed to define distinct trajectories of treatment response and assess...
Annual Review of Medicine
September 20, 2023
Ji-Woon Kim, Kanzo Suzuki, Ege T Kavalali et al.
105 citations
Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are a primary line of treatment for this mental disorder, although the delayed response and incomplete efficacy in some patients highlight the need for improved therapeutic approaches. Over the past two decades, ketamine has shown rapid onset with sustained (up to several days)...
September 19, 2023
No association was found between ketamine's dissociative symptoms and treatment response in adolescents. Adolescents receiving midazolam showed less depression improvement with higher depersonalization symptoms in 24 hours. Tricyclic antidepressants are more effective in adults than in children and adolescents.